Minimally differentiated acute myeloid leukemia (AML-M0): Comparison of 25 cases with other French-American-British subtypes

Blood

Volumn 89, Issue 2, 1997, Pages 621-629

  Venditti, Adriano ^a   Del Poeta, Giovanni ^a   Buccisano, Francesco ^a   Tamburini, Anna ^a   Cox, M Christina ^a   Stasi, Roberto ^a   Bruno, Antonio ^a   Aronica, Germano ^a   Maffei, Laura ^a   Suppo, Giovanna ^a   Simone, Maria Domenica ^a   Forte, Laura ^a   Cordero, Valeria ^a   Postorino, Massimiliano ^a   Tufilli, Vincenza ^a   Isacchi, Giancarlo ^a   Masi, Mario ^a   Papa, Giuseppe ^a   Amadori, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD2 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTARABINE; DAUNORUBICIN; DNA NUCLEOTIDYLEXOTRANSFERASE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; MONOCLONAL ANTIBODY; MYELOPEROXIDASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CLASSIFICATION; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME ABERRATION; CLINICAL FEATURE; CYTOCHEMISTRY; ENZYME ASSAY; FEMALE; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 9844222436     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.2.621     Document Type: Article

References (56)

1. Lee EJ, Pollak A, Leavitt RD, Testa JR, Schiffer CA: Minimally differentiated acute nonlymphocytic leukemia: A distinct entity. Blood 70:1400, 1987
2. Matutes E, Pombo de Olivera LZ, Foroni L, Morilla R, Catovsky D: The role of ultrastructural cytochemistry in clarifying the nature of undifferentiated cells in acute leukaemia. Br J Haematol 69:205, 1988
3. Campos L, Guyotat D, Archimbaud E, Devaux Y, Treille D, Larese A, Maupas J, Gentilhomme O, Ehrsam A, Fiere D: Surface marker expression in adult acute myeloid leukaemia: Correlations with initial characteristics, morphology and response to therapy. Br J Haematol 72:161,1989
4. Venditti A, Del Poeta G, Stasi R, Masi M, Bruno A, Buccisano F, Cox C, Coppetelli U, Aronica G, Simone MD, Tribalto M, Amadori S, Papa G: Minimally differentiated acute myeloid leukaemia (AML-M0): Cytochemical, immunophenotypic and cytogenetic analysis of 19 cases. Br J Haematol 88:784, 1994
5. Stasi R, Del Poeta G, Venditti A, Masi M, Stipa E, Dentamaro T, Cox C, Dallapiccola B, Papa G: Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia. Blood 83:1619, 1994
6. Segeren CM, de Jong-Gerritis GCMM, van't Veer MB (Dutch Slide Review Committee of Leukemia in Adults): AML-M0: Clinical entity or waste basket for immature blastic leukemias? A description of 14 patients. Ann Hematol 70:297, 1995
7. Cuneo A, Ferrant A, Michaux JL, Boogaerts M, Demuynck H, Van Orshoven A, Criel A, Stul M, Dal Cin P, Hernandez J, Chatelain B, Doyen C, Louwagie A, Castoldi G, Cassiman JJ, Van Den Berghe: Cytogenetic profile of minimally differentiated (FAB MO) acute myeloid leukemia: Correlation with clinicobiologic findings. Blood 85:3688, 1995
8. Venditti A, Del Poeta G, Stasi R, Buccisano F, Aronica G, Bruno A, Cox C, Maffei L, Tamburini A, Papa G, Amadori S: Biological profile of 23 cases of minimally differentiated acute myeloid leukemia (AML-M0) and its clinical implications. Blood 87:418, 1996 (letter)
9. Yokose N, Ogata K, Ito T, Miyake K, An E, Inokuchi K, Yamada T, Gomi S, Tanabe Y, Ohki I, Kuwabara T, Hasegawa S, Shinohara T, Dan K, Nomura T: Chemotherapy for minimally differentiated acute myeloid leukemia (AML-M0). A report on five cases and review of the literature. Ann Hematol 66:67, 1995
10. Shetty V, Chitale A, Matutes E, Buccheri V, Morilla R, Catovsky D: Immunological and ultrastructural studies in acute biphenotypic leukaemia. J Clin Pathol 46:903, 1993
11. van der Schoot CE, Daams GM, Pinkster J, Vet R, von dem Borne AEGKr: Monoclonal antibodies against myeloperoxidase are valuable immunological reagents for the diagnosis of acute myeloid leukaemia. Br J Haematol 74:173, 1990
12. Koeffler HP, Ranyard J, Pertcheck M: Myeloperoxidase: Its structure and expression during myeloid differentiation. Blood 65:484, 1985
13. Praxedes MK, Pombo de Olivera LZ, Pereira WV, Quintana IZ, Tabak DG, De Oliveira MS: Monoclonal antibody anti-MPO is useful in recognizing minimally differentiated acute myeloid leukaemia. Leuk Lymphoma 12:233, 1994
14. Campana D, Hanse-Hagge E, Matutes E, Coustan-Smith E, Yokota S, Shetty V, Bartram CR, Janossy G: Phenotypic, genotypic, cytochemical, and ultrastructural characterization of acute undifferentiated leukemia. Leukemia 4:620, 1990
15. Pombo de Oliveira LZ, Matutes E, Rani S, Morilla R, Catovsky D: Early expression of MCS2 (CD13) in the cytoplasm of blast cells from acute myeloid leukaemia. Acta Haematol 8:61, 1988
16. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (FAB Cooperative Group): Proposals for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol 78:325, 1991
17. Del Poeta G, Stasi R, Venditti A, Suppo G, Aronica G, Bruno A, Masi M, Tabilio A, Papa G: Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia 8:388, 1994
18. Del Poeta G, Stasi R, Aronica G, Venditti A, Cox MC, Bruno A, Buccisano F, Masi M, Tribalto M, Amadori S, Papa G: Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 87:1997, 1996
19. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103:620, 1985
20. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Stryckmans P, Rotoli B, Leoni P, Petermans ME, Dardenne M, Vigna ML, Petti MC, Solbu G, Sociu S, for the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Leukemia Cooperative Group: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 332:217, 1995
21. Zittoun R, Liso V, Mandelli F, Rotoli B, de Witte T, Gattinger C, Resegotti L, Caronia F, Leoni P, Petti MC, Solbu G, Vegna ML, Suciu S, for the EORTC Leukemia Cooperative Group and the GIMEMA group: Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML 8B). Leukemia 6:76, 1992 (suppl 2)
22. Resegotti L, for the GIMEMA Group: Treatment of acute non lymphoid leukemia (ANLL) in elderly patients. The GIMEMA experience. Leukemia 6:72, 1992 (suppl 2)
23. Avvisati G, Petti MC, Spadea A, Lazzarino M, Alessanrino EP, Liso V, Specchia G, Carella AM, Falda M, Fioritoni G, Ladogana F, Mandelli F, for the Cooperative group GIMEMA: Idarubicin (IDA) treatment in acute promyelocytic leukemia (APL): The GIMEMA experience. Hematologica 76:10, 1991 (suppl 4)
24. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin J, Papa G, Noens L, Ho J, O'Brien C, Matcham J, Barge A on behalf of the AML study group in Germany, Spain, Austria, United Kingdom, Italy, Belgium, Australia, Sweden and Portugal: Results of a randomised, double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de-novo acute myeloid leukemia. Blood 86:267a, 1995 (abstr, suppl 1)
25. Preisler HD: Treatment failure in AML. Blood Cells 8:585, 1982
26. Buccheri V, Matutes E, Dyer MJ, Catovsky D: Lineage commitment in biphenotypic acute leukemia. Leukemia 7:919, 1993
27. Hanker JS, Yates PE, Metz CB, Rustioni A: A new specific sensitive and non-carcinogenic reagent for the demonstration of horseradish peroxidase. Histochemistry 9:789, 1977
28. Erber WM, Mynheer LC, Mason DY: APAAP labelling of blood and bone marrow samples of phenotyping leukaemia. Lancet 10:761, 1986
29. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D: Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79:473, 1992
30. Stasi R, Del Poeta G, Masi M, Tribalto M, Venditti A, Papa G, Nicoletti B, Vernole P, Tedeschi B, Delaroche I, Mingarelli R, Della Piccola B: Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukaemia. Cancer Genet Cytogenet 67:28, 1993
31. Mitelman F (ed): ISCN: Guidelines for Cancer Cytogenetics. Supplement to an International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 1991
32. Sandberg AA: Cytogenetic features of special hematologic disorders, including some aspects of acute leukemia, in Sandberg AA (ed): The Chromosomes in Human Cancer and Leukemia (ed 2). New York, NY, Elsevier, 1990, p 374
33. Le Maistre A, Childs CA, Hirsch-Ginsberg C, Reuben J, Cork A, Trujillo JM, Andersson B, McCredie KB, Freireich E, Stass SA: Heterogeneity in acute undifferentiated leukemia. Hematol Pathol 2:79, 1988
34. Dewald GW, Schad CR, Lilla VC, Jalal SM: Frequency and photographs of HGM11 chromosome anomalies in bone marrow samples from 3966 patients with malignant hematologic neoplasms. Cancer Genet Cytogenet 68:60, 1993
35. Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, Golomb HM, Rowley JD: Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: Further evidence for characteristic abnormalities of chromosome number 5 and 7. Clin Oncol 4:325, 1986
36. Dohoner H, Arthur DC, Ball ED, Sobol RE, Davey FR, Lawrence D, Gordon L, Patil SR, Surana RB, Testa JR, Verma RS, Schiffer CA, Wurster-Hill D, Bloomfield CD: Trisomy 13: A new recurring chromosome abnormality in acute leukemia. Blood 76:1614, 1990
37. Johansson B, Billstrom R, Mauritzson N, Mitelman F: Trisomy 19 as the sole chromosomal anomaly in hematologic neoplasms. Cancer Genet Cytogenet 74:62, 1994
38. Tosi S, Stilgenbauer S, Giudici G, Capalbo S, Specchia G, Liso V, Castagna S, Ianzi E, Lichter P, Biondi A: Reciprocal translocation t(12; 13)(p13;q14) in acute nonlymphoblastic leukemia: Report and cytogenetic analysis of two cases. Cancer Genet Cytogenet 77:106, 1994
39. Berger R, Bernheim A, Sigaux F, Daniel MT, Valensi F, Flandrin G: Acute monocytic leukemia: Chromosome studies. Leuk Res 6:17, 1982
40. Parreira A, Pombo de Oliveira MS, Matutes E, Foroni L, Morilla R, Catovsky D: Terminal deoxynucleotidil transferase positive acute myeloid leukemia: An association with immature myeloblastic leukemia. Br J Haematol 69:219, 1988
41. Bradstock KF, Hewson J, Kerr A, Kabral A, Lee CH, Hughes WG: Expression of terminal deoxynucleotidil transferase in malignant myeloblasts. Am J Clin Pathol 80:800, 1983
42. Bradstock KF, Hoffbrand AV, Ganeshaguru K, Liewellin P, Patterson K, Wonke B, Prentice AG, Bennett M, Pizzolo G, Bollum FJ, Janossy G: Terminal deoxynucleotidil transferase expression in acute non-lymphoid leukemia: An analysis by immunofluorescence. Br J Haematol 47:133, 1981
43. Mc Graw TP, Folds JD, Bollum FJ, Stass SA: Terminal deoxynucleotidil transferase-positive acute myeloblastic leukemia. Am J Hematol 10:251, 1981
44. San Miguel JF, Gonzales M, Canizo MC, Anta JP, Portera JA, Lopez-Borrasca A: Tdt activity in acute myeloid leukemias defined by monoclonal antibodies. Am J Hematol 23:9, 1986
45. Lee EJ, Yang J, Leavitt RD, Testa JR, Civin CI, Forrest A, Schiffer CA: The significance of CD34 and Tdt determination in patients with untreated de novo acute myeloid leukemia. Leukemia 6:1203, 1992
46. Drexler HG, Thiel E, Ludwig WD: Acute myeloid leukemias expressing lymphoid-associated antigens: Diagnostic incidence and prognostic significance. Leukemia 7:489, 1993
47. Vinante F, Pizzolo G, Rigo A, Vincenzi C, Sorio C, Cassatella M, Berton G: The CD4 molecule belongs to the phenotypic repertoire of most cases of acute myeloid leukemia. Leukemia 6:1257, 1992
48. + hematopoietic progenitors express low levels of CD4, the high-affinity receptor for human immunodeficency virus-type 1. Blood 84:1896, 1994
49. Reuss-Borst MA, Buhring HJ, Schmidt H, Muller CA: Immunophenotypic heterogeneity and prognostic significance of C-kit expression. Leukemia 8:258, 1994
50. Creutzig U, Harbott J, Sperling C, Ritter J, Zimmermann M, Loffler H, Rhiem H, Schellong G, Ludwig WD: Clinical significance of surface antigen expression in children with acute myeloid leukemia: Results of study AML-BFM-87. Blood 86:3097, 1995
51. List AF, Spier CM, Cline A, Doll DC, Garewl H, Morgan R, Sandberg AA: Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br J Haematol 78:28, 1991
52. Haase D, Fonatsch C, Freund M, Wormann B, Bodenstein H, Bartels H, Stollmann-Gibbels B, Lengfelder E: Cytogenetic findings in 179 patients with myelodysplastic syndromes. Ann Hematol 70:171, 1995
53. Haase D, Feuring-Buske M, Koenemann S, Fonatsch C, Troff C, Verbeek W, Hiddemann W, Wormann B: Cytogenetic identification of leukemia associated abnormalities in hematopoietic stem cell of AML patients. Blood 84:308a, 1994 (abstr, suppl 1)
54. Haase D, Freund M, Weite K, Zabel K, Fonatsch C: Association of monosomy 7 and leukemic response to myeloid growth factors, in Freund M, Linke, Welte (eds): Cytokines in Hemopoiesis, Oncology and Immunology III. New York, NY, Springer, 1994, p 254
55. Haase D, Fonatsch C: Monosomy 7 provides a proliferative advantage for leukemic cells under incubation with GM-CSF in vitro. Blut 61:322, 1990
56. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P: Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 86:3542, 1995